{"rows":[{"id":1811,"title":"Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.","authors":"Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Jungaberle H, Majić T, Ströhle A, Wolff M, Wellek S, Gründer G","journal":"Neuroscience applied","publication_date":"2022-01-01","publication_year":2022,"doi":"10.1016/j.nsa.2022.100104","pubmed_id":"40656230","openalex_id":"https://openalex.org/W4220708535","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656230/","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Randomized Controlled Trial,Safety","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:20","bibtex":null,"source_record_id":"PMID:40656230","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40656230/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40656230","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656230/","doi":"10.1016/j.nsa.2022.100104","pmid":"40656230","publication_date":"2022-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1264,"title":"Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals.","authors":"Armand S, Larsen K, Madsen MK, Ozenne B, Preller KH, Knudsen GM, Stenbæk DS, Fisher PM","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2023.103934","pubmed_id":"40656071","openalex_id":"https://openalex.org/W4390452945","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656071/","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Brain Imaging,Aging,Emotional Processing","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:11","bibtex":null,"source_record_id":"PMID:40656071","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40656071/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40656071","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656071/","doi":"10.1016/j.nsa.2023.103934","pmid":"40656071","publication_date":"2024-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1263,"title":"Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.","authors":"McCulloch DE, Lopez JP, Dalla C, Castrén E, Erritzoe D, Frokjaer VG, Lundberg J, Preller KH, Fisher PM, Knudsen GM","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2023.103929","pubmed_id":"40656118","openalex_id":"https://openalex.org/W4389751274","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656118/","substance_tags":"psilocybin","topic_tags":"Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Animal Study","study_type":"Animal Study","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:11","bibtex":null,"source_record_id":"PMID:40656118","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40656118/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40656118","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656118/","doi":"10.1016/j.nsa.2023.103929","pmid":"40656118","publication_date":"2024-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1257,"title":"Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.","authors":"E-Wen McCulloch D, Liechti ME, Kuypers KP, Nutt D, Lundberg J, Stenbæk DS, Goodwin GM, Gründer G, Butlen-Ducuing F, Haberkamp M, Thirstrup S, Knudsen GM","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2024.103938","pubmed_id":"40656112","openalex_id":"https://openalex.org/W4390754521","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656112/","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology,Clinical Trial","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:10","bibtex":null,"source_record_id":"PMID:40656112","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40656112/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40656112","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656112/","doi":"10.1016/j.nsa.2024.103938","pmid":"40656112","publication_date":"2024-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1196,"title":"Safety pharmacology of acute psilocybin administration in healthy participants.","authors":"Straumann I, Holze F, Becker AM, Ley L, Halter N, Liechti ME","journal":"Neuroscience applied","publication_date":"2024-01-01","publication_year":2024,"doi":"10.1016/j.nsa.2024.104060","pubmed_id":"40656108","openalex_id":"https://openalex.org/W4392888270","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656108/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Addiction,Pharmacology,Healthy Volunteers,Safety","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:10","bibtex":null,"source_record_id":"PMID:40656108","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40656108/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40656108","source_url":"https://pubmed.ncbi.nlm.nih.gov/40656108/","doi":"10.1016/j.nsa.2024.104060","pmid":"40656108","publication_date":"2024-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":878,"title":"An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers.","authors":"Godfrey K, Weiss B, Zhang X, Spriggs M, Peill J, Lyons T, Carhart-Harris R, Erritzoe D","journal":"Neuroscience applied","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/j.nsa.2024.104092","pubmed_id":"40654586","openalex_id":"https://openalex.org/W4404933083","source_url":"https://pubmed.ncbi.nlm.nih.gov/40654586/","substance_tags":"psilocybin","topic_tags":"Consciousness,Personality Change,Healthy Volunteers","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:04","last_checked":"2026-08-09 08:28:04","bibtex":null,"source_record_id":"PMID:40654586","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40654586/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40654586","source_url":"https://pubmed.ncbi.nlm.nih.gov/40654586/","doi":"10.1016/j.nsa.2024.104092","pmid":"40654586","publication_date":"2025-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":815,"title":"A review of psychedelics trials completed in depression, informed by European regulatory perspectives.","authors":"Silva F, Butlen-Ducuing F, Guizzaro L, Balabanov P","journal":"Neuroscience applied","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/j.nsa.2025.105516","pubmed_id":"40654583","openalex_id":"https://openalex.org/W4407959310","source_url":"https://pubmed.ncbi.nlm.nih.gov/40654583/","substance_tags":"psilocybin","topic_tags":"Depression,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:04","last_checked":"2026-08-09 08:28:03","bibtex":null,"source_record_id":"PMID:40654583","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40654583/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40654583","source_url":"https://pubmed.ncbi.nlm.nih.gov/40654583/","doi":"10.1016/j.nsa.2025.105516","pmid":"40654583","publication_date":"2025-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":769,"title":"Is there room for ethics of authenticity in psilocybin research?","authors":"Jerotic S","journal":"Neuroscience applied","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/j.nsa.2025.105519","pubmed_id":"40654595","openalex_id":"https://openalex.org/W4408829649","source_url":"https://pubmed.ncbi.nlm.nih.gov/40654595/","substance_tags":"psilocybin","topic_tags":"General","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:04","last_checked":"2026-08-09 08:28:01","bibtex":null,"source_record_id":"PMID:40654595","abstract_available":false,"abstract_source":null,"abstract_source_url":null,"abstract_redistributed":false,"text_rights_status":"not_applicable_no_text","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40654595","source_url":"https://pubmed.ncbi.nlm.nih.gov/40654595/","doi":"10.1016/j.nsa.2025.105519","pmid":"40654595","publication_date":"2025-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":596,"title":"Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.","authors":"Liechti ME, Gasser P, Aicher HD, Mueller F, Hawrot T, Schmid Y","journal":"Neuroscience applied","publication_date":"2025-01-01","publication_year":2025,"doi":"10.1016/j.nsa.2025.105525","pubmed_id":"40800003","openalex_id":"https://openalex.org/W4412792405","source_url":"https://pubmed.ncbi.nlm.nih.gov/40800003/","substance_tags":"psilocybin","topic_tags":"General","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:04","last_checked":"2026-08-09 08:27:57","bibtex":null,"source_record_id":"PMID:40800003","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/40800003/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:40800003","source_url":"https://pubmed.ncbi.nlm.nih.gov/40800003/","doi":"10.1016/j.nsa.2025.105525","pmid":"40800003","publication_date":"2025-01-01","importer_version":"2.1.3","text_redistributed":false}}],"total":9,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Neuroscience applied","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}